Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer
The purpose of this study is to investigate the effects of tumor associated macrophage (TAM) in advanced non-small cell lung cancer (NSCLC) patients on the treatment response and outcome of these subjects. Pathologic specimens from tissue bank will be stained by immunostaining methods with CD68 antibody. The clinical treatment response and outcomes will be analyzed between high or low TAM.
Advanced Nonsmall Cell Lung Cancer
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Tumor-Associated Macrophages Correlate With Response and Outcomes in Advanced Non-Small Cell Lung Cancer After First Line Treatment.|
- Response to treatment of advanced NSCLC with high or low TAM. [ Time Frame: 2-3 months ] [ Designated as safety issue: No ]All patients with advanced non-small cell lung cancer (NSCLC) who had been treated were included. The decision of advanced NSCLC treatment was a consensus by the patient and clinician, and approved by team conference (including the oncologists, pulmonologists, pathologists, radiologists, surgeons, radiation oncologists, and nuclear medicine specialists). The tumor response was evaluated using computerized tomography according to the Response Evaluation Criteria in Solid Tumors (RECIST). The treatment response of advanced between high and low TAM patients were compared.
- Outcomes of advanced NSCLC with high and low TAM. [ Time Frame: 12-24 months ] [ Designated as safety issue: No ]The outcomes of advanced NSCLC with high and low TAM will be compared. The outcomes include overall survival (OS) and progression-free survival (PFS). Survival curves were estimated by the Kaplan-Meier method while the log-rank test was used to compare the patient survival times per groups.
Biospecimen Retention: Samples With DNA
All specimens were fixed in 10% buffered formalin and embedded in paraffin according to standard procedures. All of the tissues were fixed immediately after biopsy, with time from tissue acquisition to fixation as short as possible. Serial sections (4 μm thickness) placed on positively charged slides (Menzel-Glasser, German) were used for immuno-histochemistry.
|Study Start Date:||January 2006|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Advanced NSCLC with high TAM
All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
Advanced NSCLC with low TAM
All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01551251
|Chang Gung Memorial Hospital|
|Taipei, Taiwan, 10507|
|Sant Paul Hospital|
|Principal Investigator:||Fu-Tsai Chung, M.D.||Chang Gung Memorial Hospital|